---
title: Dexmedetomidine Wound Infiltration in Cesarean Section
nct_id: NCT03382938
overall_status: RECRUITING
phase: NA
sponsor: Attikon Hospital
study_type: INTERVENTIONAL
primary_condition: Postoperative Pain
countries: Greece
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03382938.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03382938"
ct_last_update_post_date: 2025-03-19
last_seen_at: "2026-05-12T07:31:03.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Dexmedetomidine Wound Infiltration in Cesarean Section

**Official Title:** Wound Infiltration With Dexmedetomidine in Cesarean Section: Effect on Postoperative Analgesia

**NCT ID:** [NCT03382938](https://clinicaltrials.gov/study/NCT03382938)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Attikon Hospital
- **Conditions:** Postoperative Pain
- **Start Date:** 2019-08-23
- **Completion Date:** 2026-11-20
- **CT.gov Last Update:** 2025-03-19

## Brief Summary

The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction.

One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).

## Detailed Description

Parturients undergoing scheduled cesarean section under combined spinal-epidural anesthesia will be included in the study. Women will be randomly allocated according to the type of the solution used for wound infiltration into one of the following four groups using the closed envelop method.

Group DEX: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of dexmedetomidine 1γ/kg within Normal Saline will be infiltrated subcutaneously along the skin wound edges.

Group ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of ropivacaine 0.375% will be infiltrated subcutaneously along the skin wound edges.

Group DEX-ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% will be infiltrated subcutaneously along the skin wound edges.

Placebo Group: Following the closure of the uterine incision and the rectus fascia, 20 ml with 0.9 % saline solution will be infiltrated subcutaneously along the skin wound edges.

In Postanesthesia Care Unit, 2 mg of morphine will be administered bolus epidurally before the removal of the epidural catheter. Postoperative analgesia will be managed with the systematic administration of intravenous paracetamol 1g x 3 /day, oral celecoxib 200mg x 2 /day and PCA morphine (1 mg/ml) (setting: bolus dose 1 ml every 7 min). The total morphine consumption 24 hours after the PCA device initiation will be recorded.

Also, ranitidine 50 mg and metoclopramide 10 mg will be given intravenously twice per day, while ondansetron 4 mg will be prescribed to be administered intravenously in case of postoperative nausea or vomiting (max x 3 times/day).

Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale (VAS, 0-10) at 1, 3, 6, 12, 18 and 24 hours after the end of surgery from an anesthesiologist who does not know the group assignment. Also, at the same time points, hemodynamic parameters of the parturients, side effects (nausea, vomiting, sedation, pruritus) and complications (fever, infection in the area of the wound infiltration, bleeding) will be recorded, while 24 hours postoperatively the overall patient' satisfaction with her postoperative analgesia management will be assessed using a 4 point scale.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* pregnancy \>37 weeks, ASA I-II, BMI\<35

Exclusion Criteria:

* patient refusal, epilepsy, GERD, morbid obesity, drug allergy, ASA class \>2, presence of atrioventricular block, severe systemic disease, multiple gestation, high risk pregnancy, contraindications to epidural technique, a history of severe systemic disease, recreational drug or alcohol use
```

## Arms

- **Dexmedetomidine** (ACTIVE_COMPARATOR) — Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
- **Ropivacaine** (ACTIVE_COMPARATOR) — Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
- **Dexmedetomidine - Ropivacaine** (ACTIVE_COMPARATOR) — Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
- **0.9 % saline** (PLACEBO_COMPARATOR) — Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration

## Interventions

- **Dexmedetomidine** (DRUG) — WOUND INFILTRATION IN CESAREAN SECTION
- **Ropivacaine** (DRUG) — WOUND INFILTRATION IN CESAREAN SECTION
- **Dexmedetomidine - Ropivacaine** (DRUG) — WOUND INFILTRATION IN CESAREAN SECTION
- **0,9% saline** (OTHER) — placebo WOUND INFILTRATION IN CESAREAN SECTION

## Primary Outcomes

- **Pain score** _(time frame: up to 24 hours after the end of surgery)_ — Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale (VAS, 0-10)

## Secondary Outcomes

- **morphine consumption** _(time frame: 24 hours after the PCA device initiation will be recorded)_
- **overall patient satisfaction** _(time frame: 24 hours after the end of surgery)_

## Locations (1)

- Paraskevi K Matsota, Athens, Other, Greece — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.paraskevi k matsota|athens|other|greece` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03382938.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03382938*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*